Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

The company has three clinical CAR-T programmes backed by its precision-targeting cellular system Imod platform technology.

Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes ...

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients' cancer without aggressive surgery.

RECORD numbers of cancers are being diagnosed early when they are more curable, NHS figures show. Nearly six in ten of the 13 ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical ...

The system is based on novel technology that promises to simplify treatment and delivery and increase the number of patients ...